Allspring Global Investments Holdings LLC Has $12.91 Million Stake in AstraZeneca PLC (NASDAQ:AZN)

Allspring Global Investments Holdings LLC increased its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 15.7% during the first quarter, Holdings Channel.com reports. The institutional investor owned 177,836 shares of the company’s stock after purchasing an additional 24,141 shares during the period. Allspring Global Investments Holdings LLC’s holdings in AstraZeneca were worth $12,911,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Dynamic Advisor Solutions LLC increased its holdings in AstraZeneca by 58.4% during the first quarter. Dynamic Advisor Solutions LLC now owns 13,055 shares of the company’s stock worth $960,000 after buying an additional 4,811 shares during the last quarter. Geode Capital Management LLC boosted its position in AstraZeneca by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 498,831 shares of the company’s stock worth $32,683,000 after purchasing an additional 5,384 shares during the period. Dorsey & Whitney Trust CO LLC boosted its position in AstraZeneca by 0.5% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 35,300 shares of the company’s stock worth $2,313,000 after purchasing an additional 189 shares during the period. Brandywine Global Investment Management LLC bought a new position in AstraZeneca during the fourth quarter worth $28,071,000. Finally, Farther Finance Advisors LLC boosted its position in AstraZeneca by 13.1% during the first quarter. Farther Finance Advisors LLC now owns 6,083 shares of the company’s stock worth $442,000 after purchasing an additional 706 shares during the period. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, BNP Paribas initiated coverage on shares of AstraZeneca in a research report on Tuesday, April 15th. They set an “outperform” rating and a $75.00 price objective for the company. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $85.00.

AstraZeneca Trading Down 2.2%

AZN stock opened at $69.60 on Friday. The company has a fifty day moving average price of $70.78 and a two-hundred day moving average price of $70.58. The stock has a market cap of $215.85 billion, a price-to-earnings ratio of 27.95, a price-to-earnings-growth ratio of 1.31 and a beta of 0.37. AstraZeneca PLC has a one year low of $61.24 and a one year high of $87.68. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.90 and a quick ratio of 0.70.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.14. The company had revenue of $13.59 billion during the quarter, compared to analysts’ expectations of $13.71 billion. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. AstraZeneca’s quarterly revenue was up 7.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.06 earnings per share. Equities analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.